Medicenna Therapeutics Corp (MDNAF)

OTCMKTS: MDNAF · Delayed Price · USD
1.230
0.00 (0.00%)
Mar 27, 2024, 12:00 AM EDT - Market open
Market Cap 85.65M
Revenue (ttm) n/a
Net Income (ttm) -8.76M
Shares Out 69.64M
EPS (ttm) -0.13
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 33,914
Open n/a
Previous Close 1.230
Day's Range n/a
52-Week Range 0.158 - 1.300
Beta 0.71
Analysts n/a
Price Target n/a
Earnings Date n/a

About MDNAF

Medicenna Therapeutics Corp., a clinical stage immunotherapy company, develops and commercializes Empowered Cytokines (EC) and Superkines for the treatment of cancer. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that is in the Phase 2b clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA57 for solid tumors and non-malignant cells of the tumor micro-environment; MDNA109, an IL-2 agonist to... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Employees 7
Stock Exchange OTCMKTS
Ticker Symbol MDNAF
Full Company Profile

Financial Performance

Financial Statements

News

Medicenna to Provide Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming American Association for Cancer Research Annual Meeting

Pre-clinical data on Medicenna's first-in-class Masked and Tumor Targeted Bifunctional Superkine, MDNA113, will also be presented at the Annual Meeting Pre-clinical data on Medicenna's first-in-class ...

22 days ago - GlobeNewsWire

Medicenna Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Corporate Update

With the Response Rate increasing to 23%, MDNA11 continues to show compelling single-agent activity in the ABILITY-1 study amongst high-dose phase-2 eligible patients (N=13) that failed checkpoint inh...

6 weeks ago - GlobeNewsWire

Medicenna Announces First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors

TORONTO and HOUSTON, Feb. 13, 2024 (GLOBE NEWSWIRE) --  Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the dev...

6 weeks ago - GlobeNewsWire

Medicenna Announces Appointment of New Auditor

TORONTO and HOUSTON, Jan. 12, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTC: MDNAF), a clinical-stage immunotherapy company focused on the develo...

2 months ago - GlobeNewsWire

Medicenna Commences Enrollment in the ABILITY-1 Study Combining MDNA11 with Pembrolizumab

TORONTO and HOUSTON, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the deve...

2 months ago - GlobeNewsWire

Medicenna Extends Period to Exercise Certain Warrants

TORONTO and HOUSTON, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical stage immunotherapy company focused on the deve...

3 months ago - GlobeNewsWire

Medicenna Announces Trading on the OTCQB Under the Symbol MDNAF

TORONTO and HOUSTON, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the deve...

3 months ago - GlobeNewsWire

Medicenna Announces Compelling Survival Benefit from Phase 2b Study of Bizaxofusp in Recurrent Glioblastoma at the 28th Annual Meeting of the Society for NeuroOncology

Single treatment of bizaxofusp doubled mOS (14.5 months vs. 7.2 months) irrespective of IL4R expression (high or low) compared to patients treated in the external control arm

4 months ago - GlobeNewsWire

Medicenna Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Operational Highlights

Cash runway extended through multiple data readouts and into Q1 of calendar 2025 MDNA11 is generally well tolerated and continues to demonstrate encouraging single-agent activity from Phase 1 portion ...

4 months ago - GlobeNewsWire

Medicenna to Present 4 Year Follow-up Phase 2b Bizaxofusp Survival Data in Recurrent Glioblastoma at the Society for Neuro-Oncology 2023 Annual Meeting

TORONTO and HOUSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTC: MDNAF), a clinical-stage immunotherapy company focused on the develo...

5 months ago - GlobeNewsWire

Medicenna Announces Promising Single-Agent Response and Durability of MDNA11 in the Phase 1/2 ABILITY Study During Dose Escalation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

MDNA11 continues to demonstrate encouraging single-agent activity from the dose escalation and evaluation portion of the ABILITY-1 Study including deep ongoing partial responses with 100% reduction of...

5 months ago - GlobeNewsWire

Medicenna Announces Nasdaq Delisting and Cutback of Management Team

The Company's listing on the Toronto Stock Exchange will not be impacted The Company's listing on the Toronto Stock Exchange will not be impacted

5 months ago - GlobeNewsWire

Medicenna Therapeutics Doses First Patient in Phase 2 Monotherapy Dose Expansion Portion of the ABILITY Study Evaluating MDNA11 in Select Types of Solid Tumors

New data from the Phase 1 dose-escalation and evaluation portion of the trial will be presented at the Society of Immunotherapy for Cancer (SITC) Annual Meeting on November 4, 2023

5 months ago - GlobeNewsWire

Medicenna Announces Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer's (SITC)

TORONTO and HOUSTON, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ, TSX: MDNA), a clinical-stage immunotherapy company focused on the developmen...

5 months ago - GlobeNewsWire

Medicenna Therapeutics Appoints Humphrey Gardner, M.D., as Chief Medical Officer

Dr. Gardner brings over 30 years of experience leading clinical development to support innovative oncology programs and translational research at global biopharmaceutical companies and major academic ...

6 months ago - GlobeNewsWire

Medicenna Announces Results of Annual and Special Meeting of Shareholders

TORONTO and HOUSTON, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ, TSX: MDNA), a clinical-stage immuno-oncology company focused on the develop...

6 months ago - GlobeNewsWire

Medicenna to Present at the AACR Special Conference Cancer Research: Tumor Immunology and Immunotherapy

TORONTO and HOUSTON, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ, TSX: MDNA), a clinical-stage immunotherapy company focused on the developme...

6 months ago - GlobeNewsWire

Medicenna Announces the Appointment of Jeff Caravella as Chief Financial Officer

Jeff Caravella brings over two decades of healthcare expertise steering strategic, financial and operational functions at leading public life-science corporations

7 months ago - GlobeNewsWire

Medicenna Establishes Boston Presence, Appoints Brent Meadows as Chief Business Officer, and Bolsters Management

TORONTO and HOUSTON, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical-stage immunotherapy company, announced today the...

8 months ago - GlobeNewsWire

Medicenna Completes MDNA11 Dose Escalation and Commences Monotherapy Dose Expansion in the Phase 1/2 ABILITY Study

- Durable anti-cancer activity was observed during monotherapy dose escalation without dose-limiting toxicities - Late-stage pancreatic cancer patient achieved 80% tumor shrinkage with complete regres...

8 months ago - GlobeNewsWire

Medicenna Appoints Dr. Arash Yavari as Chair of Development Advisory Committee

Development Advisory Committee strengthened with the expertise and leadership of Dr. Yavari Development Advisory Committee strengthened with the expertise and leadership of Dr. Yavari

8 months ago - GlobeNewsWire

Medicenna Therapeutics to Provide Clinical Update from Phase 1/2 ABILITY Study on August 9, 2023

TORONTO and HOUSTON, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical-stage immunotherapy company, announced today tha...

8 months ago - GlobeNewsWire

Medicenna Strengthens IP Portfolio with U.S. Patent Granted for the Use of Interleukin-2 Superkine Fusion Proteins in Oncology

TORONTO and HOUSTON, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced the...

8 months ago - GlobeNewsWire

Medicenna Reports First Quarter Fiscal 2024 Financial Results and Operational Highlights

TORONTO and HOUSTON, July 28, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical-stage immunotherapy company, today announced fin...

8 months ago - GlobeNewsWire

Medicenna Presents at National Brain Tumor Society's Research Round Table

TORONTO and HOUSTON, July 25, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced tha...

8 months ago - GlobeNewsWire